Senzer Ltd has announced plans to launch several inhaled cannabinoid products in the UK, beginning with its Cannafen cannabidiol inhalation solution later this year. Senzer is a subsidiary of Kind Consumer, whose Voke nicotine inhaler was approved by the MHRA for nicotine cessation in 2014.
The company will launch the inhaled cannabinoid product under a specials pharmaceutical license allowing doctors to prescribe the inhalation solution to cancer patients for the relief of side effects from chemotherapy. A spokesperson said, “We believe we have a unique respiratory delivery system for cannabinoids that can hopefully improve the quality of life for those going through extremely intense treatment.”
A dronabinol inhalation solution product called Candex is expected to launch in the UK in early 2019. Earlier this year, Insys announced that it would soon begin clinical research for a breath activated dronabinol inhaler based on Senzer’s delivery technology.
Read the Senzer press release.
